RRD2 Antibody

What is DDR2 and what functions does it serve in cellular processes?

DDR2 is a receptor tyrosine kinase that functions as a collagen receptor, mediating cell-matrix communication. It consists of an extracellular discoidin domain (spanning amino acids Gln24-Arg399 in humans), a transmembrane region, and an intracellular kinase domain . Unlike most receptor tyrosine kinases that respond to soluble ligands, DDR2 is uniquely activated by fibrillar collagens, particularly types I and II. Upon collagen binding, DDR2 undergoes autophosphorylation at specific tyrosine residues, triggering downstream signaling cascades that regulate diverse cellular processes including cell proliferation, migration, and extracellular matrix remodeling .

DDR2 exhibits distinct expression patterns, with high expression observed in fibroblasts, including human rheumatoid arthritis synovial fibroblasts (RASF) and human dermal fibroblasts (HDF), while being absent or minimally expressed in certain other cell types . This expression profile contributes to its tissue-specific functions in matrix regulation.

How can I verify DDR2 antibody specificity in my experimental system?

Verifying DDR2 antibody specificity requires multiple complementary approaches:

• Knockdown validation: Transfect cells with DDR2-specific siRNA (siDDR2) alongside non-targeting control siRNA (siNT). Western blot analysis should show significant reduction in the DDR2 band in siDDR2-treated samples compared to controls . This approach definitively confirms antibody specificity to DDR2.

• Expression pattern analysis: Compare DDR2 detection across multiple cell lines with known differential expression. For example, both RASF and HDF express DDR2 but not DDR1, while HT1080 human fibrosarcoma cells express both DDR1 and DDR2 . The antibody should detect DDR2 at the expected molecular weight (~130-139 kDa) only in cell types known to express it.

• Phospho-specificity testing: For phospho-specific DDR2 antibodies, treat cells with and without collagen stimulation or phosphatase inhibitors like Calyculin A. The phospho-DDR2 signal should increase after treatments that enhance phosphorylation .

• Recombinant protein controls: If available, include lysates from cells transfected with recombinant DDR2 as positive controls alongside untransfected cells .

What are the key phosphorylation sites in DDR2 and their significance?

The key phosphorylation sites in DDR2 include:

DDR2 phosphorylation exhibits a distinctive temporal profile, with phosphorylation increasing over 24 hours following collagen stimulation, unlike the rapid and transient phosphorylation seen with most other receptor tyrosine kinases . This sustained phosphorylation pattern allows DDR2 to mediate long-term cellular responses to collagen in the extracellular matrix.

Specific phosphorylation sites serve as critical biomarkers for DDR2 activation status and can be detected using phospho-specific antibodies such as those targeting the Y740 residue .

How does DDR2 signaling differ from integrin-mediated collagen signaling pathways?

DDR2 and integrin signaling represent parallel but functionally distinct collagen-responsive pathways with different mechanistic and temporal characteristics:

• Differential activation of matrix metalloproteinases: DDR2, but not β1 integrin, mediates collagen-induced activation of MT1-MMP (membrane type 1 matrix metalloproteinase) and subsequent MMP-2 activation in rheumatoid arthritis synovial fibroblasts (RASF) . Knockdown experiments demonstrate that siRNA against DDR2 significantly reduces collagen-induced MT1-MMP expression and MMP-2 activation, while β1 integrin knockdown does not affect these processes .

• Different temporal dynamics: DDR2 phosphorylation exhibits a uniquely sustained profile, developing over 24 hours after collagen stimulation, whereas integrin signaling typically shows more rapid activation kinetics .

• Distinct collagen recognition mechanisms: DDR2 binds specifically to triple-helical collagen motifs through its discoidin domain, while integrins recognize different epitopes on collagen fibrils. This is evidenced by the fact that inhibitory (6S6) or activating (P4G11) antibodies against β1 integrin do not affect collagen-induced MT1-MMP expression or MMP-2 activation .

• Differential effects on cellular invasion: siRNA-mediated knockdown of DDR2 significantly impairs RASF invasion through collagen matrices, whereas β1 integrin knockdown has no significant effect in these cells . This indicates DDR2's specific role in mediating collagen-dependent invasion processes.

What mechanisms regulate DDR2-dependent activation of matrix metalloproteinases?

DDR2 regulates matrix metalloproteinases through multiple interconnected mechanisms:

• MT1-MMP expression regulation: Collagen stimulation of DDR2 leads to increased MT1-MMP expression at both protein and transcriptional levels in RASF cells. This effect is abrogated by DDR2 knockdown but not by β1 integrin knockdown .

• Tyrosine kinase activity dependence: The kinase inhibitor dasatinib blocks collagen-induced MT1-MMP expression and subsequent MMP-2 activation, demonstrating that DDR2's tyrosine kinase activity is essential for this signaling pathway .

• SHP-2 phosphorylation: DDR2 phosphorylates the tyrosine phosphatase SHP-2 at multiple sites (including Tyr62 and Tyr542) in a kinase-dependent manner. This phosphorylation increases over time following collagen stimulation, paralleling DDR2's own phosphorylation profile . Kinase-dead DDR2 mutants (K608M and K608E) fail to induce SHP-2 phosphorylation, confirming the direct relationship .

• Collagen type specificity: DDR2 mediates MT1-MMP upregulation and MMP-2 activation in response to both human and bovine collagen II, suggesting conservation of the relevant collagen binding motifs across species .

• Matrix degradation capacity: DDR2 signaling enables cells to degrade not only collagen but also other matrix components like gelatin, as demonstrated in film degradation assays .

How can I optimize detection of phosphorylated DDR2 in experimental systems?

Detecting phosphorylated DDR2 requires careful optimization due to its unique phosphorylation dynamics and potential technical challenges:

What approaches are effective for studying DDR2 mutations identified in cancer?

DDR2 mutations have been identified in various cancers, particularly lung squamous cell carcinoma (SCC). Effective approaches for studying these mutations include:

• Functional domain mapping: Position mutations within DDR2's domain structure to predict potential functional consequences. Key domains include the discoidin domain (ligand binding), transmembrane region, juxtamembrane domain, and kinase domain .

• 3D collagen gel assays: Culture cells expressing wild-type or mutant DDR2 in three-dimensional collagen I matrices to assess colony formation capacity. This provides a physiologically relevant context for studying how mutations affect DDR2-collagen interactions and downstream signaling .

• Phosphorylation profiling:

  • Compare phosphorylation patterns between wild-type and mutant DDR2 using phospho-specific antibodies

  • Employ quantitative SRM mass spectrometry to precisely measure differences in site-specific phosphorylation (e.g., Y736, Y740/741) between wild-type and mutant receptors

  • Assess temporal dynamics of phosphorylation following collagen stimulation

• Downstream signaling analysis:

  • Examine the effect of DDR2 mutations on SHP-2 phosphorylation, a key downstream mediator

  • Compare phospho-SHP-2 levels at multiple sites (Y62, Y542) between wild-type and mutant DDR2-expressing cells

  • Evaluate MT1-MMP expression and MMP-2 activation in response to collagen stimulation

• Combining mutational and pharmacological approaches:

  • Test sensitivity of different DDR2 mutants to kinase inhibitors like dasatinib

  • Assess how mutations affect interaction with scaffold proteins or other signaling components

What techniques are most reliable for detecting DDR2 protein expression and activation?

Several complementary techniques provide robust detection of DDR2 expression and activation:

• Western Blotting: Traditional immunoblotting using DDR2-specific antibodies detects total DDR2 protein at approximately 130-139 kDa. For optimal results:

  • Use reducing conditions

  • Include positive controls (e.g., HEK293 cells transfected with human DDR2)

  • Compare with negative controls or knockdown samples

  • Probe for phosphorylation using either phospho-specific antibodies or generic phosphotyrosine antibodies (4G10, pY100)

• Simple Western™ (Capillary-based immunoassay):

  • Offers increased sensitivity and reproducibility compared to traditional Western blotting

  • Can reliably detect DDR2 at lower sample concentrations (0.2 mg/mL lysate)

  • Provides precise molecular weight determination

  • Works effectively for both total DDR2 and phosphorylated DDR2 detection

• Selected Reaction Monitoring (SRM) Mass Spectrometry:

  • Enables precise quantification of site-specific phosphorylation events

  • Can detect significant changes in phosphorylation at Y736 and Y740/741 residues

  • Provides quantitative data suitable for statistical analysis

  • Particularly valuable for comparing wild-type versus mutant DDR2 phosphorylation profiles

• Functional Assays:

  • Collagen film degradation assays measure MT1-MMP activity downstream of DDR2 activation

  • Transwell collagen invasion assays assess the functional impact of DDR2 on cell invasion

  • 3D collagen gel colony formation assays evaluate DDR2-dependent growth and survival

What controls should be included when using DDR2 antibodies in experimental protocols?

Robust experimental design requires appropriate controls to ensure reliable interpretation of DDR2 antibody results:

• Positive Controls:

  • Cell lines with confirmed DDR2 expression (RASF, HDF)

  • HEK293 cells transfected with human DDR2 expression constructs

  • Cells treated with collagen I (for phosphorylation studies)

  • Cells treated with Calyculin A (for maximal phosphorylation induction)

• Negative Controls:

  • Cell lines lacking DDR2 expression

  • DDR2 knockdown samples (using validated siRNA)

  • Untreated cells (for phosphorylation studies)

  • Kinase-dead DDR2 mutants (K608M, K608E) to confirm kinase-dependent effects

• Specificity Controls:

  • Secondary antibody-only controls to assess non-specific binding

  • Peptide competition assays to confirm epitope specificity

  • Comparison with other DDR2 antibodies targeting different epitopes

  • Parallel detection of closely related proteins (e.g., DDR1) to confirm specificity

• Functional Validation Controls:

  • siRNA knockdown with rescue experiments (re-expression of siRNA-resistant DDR2)

  • Pharmacological inhibition (e.g., dasatinib) to confirm kinase-dependent functions

  • Parallel assessment of β1 integrin function to distinguish DDR2-specific effects

How can in vitro kinase assays be optimized for studying DDR2 enzymatic activity?

In vitro kinase assays provide valuable insights into DDR2's catalytic properties and can be optimized as follows:

What are the key considerations for using siRNA to study DDR2 function?

siRNA-mediated knockdown is a powerful approach for studying DDR2 function but requires careful optimization:

• siRNA design and validation:

  • Use validated siRNA sequences targeting DDR2 (siDDR2)

  • Include non-targeting siRNA controls (siNT) in all experiments

  • Confirm knockdown efficiency by Western blotting for DDR2 protein (~48 hours post-transfection)

  • Verify specificity by showing that related proteins (e.g., DDR1) remain unaffected

• Experimental timing:

  • Allow sufficient time after transfection (typically 48 hours) to achieve maximal protein knockdown

  • For collagen stimulation experiments, add collagen after confirming knockdown and continue culture for an additional 48-72 hours

  • Design time-course studies to account for DDR2's slow activation kinetics

• Functional readouts:

  • Assess effects on downstream targets like MT1-MMP expression and MMP-2 activation

  • Perform collagen film degradation assays to measure matrix remodeling capacity

  • Use Transwell collagen invasion assays to evaluate migration/invasion potential

  • Compare effects with other targeted knockdowns (e.g., β1 integrin) to establish pathway specificity

• Combined approaches:

  • Perform rescue experiments by expressing siRNA-resistant DDR2 constructs

  • Compare siRNA effects with pharmacological inhibition using dasatinib or other RTK inhibitors

  • Combine siDDR2 with knockdown of other pathway components to assess cooperative effects

How does DDR2 phosphorylation pattern differ from other receptor tyrosine kinases?

DDR2 exhibits unique phosphorylation characteristics that distinguish it from typical receptor tyrosine kinases:

• Temporal dynamics: Unlike most RTKs that activate within minutes, DDR2 phosphorylation develops gradually over hours, reaching maximal levels approximately 24 hours after collagen stimulation . This slow kinetic profile reflects DDR2's role in mediating sustained responses to the stable extracellular matrix environment.

• Site-specific patterns: Different phosphorylation sites on DDR2 show distinct temporal profiles in response to collagen stimulation, suggesting differential regulation of individual sites. Quantitative SRM analysis demonstrates significant increases in phosphorylation at activation loop sites (Y736, Y740/741) 24 hours post-stimulation .

• Kinase-dependency: DDR2 phosphorylation requires its intrinsic kinase activity, as kinase-dead mutants (K608M, K608E) fail to undergo phosphorylation even after collagen exposure. This contrasts with some RTKs that can be partially phosphorylated by other kinases in trans .

• Substrate specificity: DDR2 exhibits specific substrate preferences, phosphorylating SHP-2 at multiple sites (Y62, Y542) with temporal patterns that parallel its own activation . This specificity contributes to DDR2's unique signaling outputs.

• Mutation effects: Cancer-associated DDR2 mutations can significantly alter phosphorylation patterns. Certain lung SCC-derived mutants show either enhanced or reduced phosphorylation compared to wild-type DDR2, affecting both receptor activation and downstream substrate phosphorylation .

What are the challenges in distinguishing between DDR1 and DDR2 in experimental systems?

Distinguishing between the closely related receptors DDR1 and DDR2 presents several challenges that require careful methodological approaches:

• Antibody specificity: Select antibodies validated for specificity against epitopes unique to DDR2 (e.g., those targeting the extracellular domain spanning Gln24-Arg399) . Always validate antibody specificity using cell lines with known differential expression of DDR1 and DDR2.

• Expression profiling: Characterize model systems by analyzing DDR1 and DDR2 expression patterns. For example, RASF and HDF express DDR2 but not DDR1, while HT1080 cells express both receptors . Western blot analysis with specific antibodies can establish the receptor expression profile of your experimental system.

• Molecular weight discrimination: DDR1 and DDR2 have similar molecular weights, but DDR2 typically appears at approximately 130-139 kDa while DDR1 runs slightly differently on SDS-PAGE. Use high-resolution gel systems or Simple Western technology for better separation .

• Functional discrimination: Design experiments exploiting known functional differences between DDR1 and DDR2:

  • DDR2 preferentially binds fibrillar collagens (types I, II, III)

  • DDR1 and DDR2 can activate distinct downstream pathways

  • Use selective knockdown to confirm receptor-specific functions

• Phosphorylation site specificity: Use phospho-specific antibodies targeting sites unique to each receptor. For example, phospho-DDR1 (Y796)/DDR2 (Y740) antibodies can detect phosphorylation at homologous but distinct sites in each receptor .

How can I effectively use DDR2 antibodies to study cancer-associated DDR2 mutations?

Studying cancer-associated DDR2 mutations requires specialized approaches:

• Mutation panel characterization:

  • Generate expression constructs for wild-type DDR2 and various cancer-associated mutants

  • Use antibodies against total DDR2 to confirm comparable expression levels

  • Organize mutations by domain location (discoidin domain, juxtamembrane region, kinase domain)

• Phosphorylation analysis:

  • Compare phosphorylation patterns between wild-type and mutant DDR2 using phospho-specific antibodies

  • Employ quantitative SRM mass spectrometry to precisely measure differences in site-specific phosphorylation

  • Evaluate temporal dynamics of phosphorylation following collagen stimulation

• Functional characterization:

  • Assess colony formation capacity in 3D collagen gels, which can reveal significant differences between wild-type and mutant DDR2

  • Analyze downstream signaling by measuring SHP-2 phosphorylation at multiple sites (Y62, Y542)

  • Conduct collagen-dependent cellular assays (invasion, matrix degradation) to determine functional consequences

• Comparative analyses:

  • Create data visualization tools (e.g., heat maps) to compare phosphorylation patterns across multiple mutants

  • Perform statistical analysis to identify significant differences between wild-type and mutant DDR2

  • Correlate molecular findings with clinical data when available

• Inhibitor sensitivity:

  • Determine how mutations affect sensitivity to DDR2 inhibitors like dasatinib

  • Use phospho-specific antibodies to monitor inhibition of DDR2 and downstream substrate phosphorylation

  • Identify mutations that confer resistance to kinase inhibitors

What emerging technologies might enhance DDR2 antibody applications in research?

Several emerging technologies hold promise for advancing DDR2 antibody applications:

• Proximity ligation assays (PLA) can detect DDR2 interactions with binding partners like collagen or SHP-2 with subcellular resolution, enabling visualization of where and when these interactions occur in intact cells.

• CRISPR-Cas9 genome editing enables precise modification of endogenous DDR2, allowing study of mutations in their native genomic context rather than through overexpression systems .

• Advanced mass spectrometry approaches beyond SRM, such as data-independent acquisition (DIA), could provide deeper coverage of the DDR2 phosphoproteome and interactome .

• Single-cell phospho-protein analysis would reveal heterogeneity in DDR2 activation within cell populations, particularly relevant for cancer research.

• Intravital imaging with fluorescently-tagged antibodies could track DDR2 activation in living tissues, providing insights into its function in physiological contexts.

These technologies, combined with existing DDR2 antibodies, will enable more comprehensive understanding of DDR2 biology and its role in disease processes.

How might DDR2 antibodies contribute to understanding extracellular matrix remodeling in disease?

DDR2 antibodies offer valuable tools for unraveling the complex relationship between collagen sensing and matrix remodeling in various diseases:

• Rheumatoid arthritis: DDR2 antibodies can help elucidate how synovial fibroblasts sense and respond to collagen changes during disease progression. Current research demonstrates DDR2's critical role in MT1-MMP activation and subsequent matrix degradation in rheumatoid arthritis synovial fibroblasts .

• Fibrosis: By monitoring DDR2 phosphorylation status during fibrotic processes, researchers can track feedback mechanisms between collagen accumulation and cellular responses that either promote or inhibit further fibrosis.

• Cancer invasion: DDR2 antibodies enable detailed analysis of how tumor cells utilize collagen signaling to activate matrix-degrading enzymes, facilitating invasion. The finding that DDR2 knockdown significantly reduces collagen invasion suggests therapeutic potential in targeting this pathway .

• Mutation analysis: Phospho-specific DDR2 antibodies can identify how cancer-associated mutations alter collagen-induced signaling, potentially explaining why certain mutations promote invasive phenotypes .

• Therapeutic development: As inhibitors targeting DDR2 advance into clinical development, phospho-specific antibodies will be essential for monitoring target engagement and pathway inhibition, particularly in matrix-rich tissues where DDR2 signaling may be most active.